Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044

Vanda Pharmaceuticals is set to launch BYSANTI for bipolar I disorder and schizophrenia in the second half of 2026, supported by FDA approval and patent protection until 2044. The company’s strong late-stage pipeline and financial position underpin plans for commercial expansion and multiple product launches through 2027.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.